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Abstract
Purpose Children with bronchopulmonary dysplasia often develop complications that affect them well into adult life. Very 
little is known about how this affects their quality of life, since no sensitive instrument is available to measure health-related 
quality of life in this population. In this study, a Dutch parent-proxy instrument was developed for this purpose.
Methods A list of items was generated after literature search and interviews with both parents of patients and clinical experts. 
Clinically relevant items were selected with the clinical impact method and item analysis. Results of clinical tests to measure 
complications in children with bronchopulmonary dysplasia were correlated with these items to select the items that show 
construct validity. Cronbach’s alpha was calculated to estimate internal consistency of the items in the final questionnaire.
Results In total, 92 children and their parents and 7 clinicians participated. Of 130 identified items, 47 showed clinical 
relevance. Spirometry, the Child Behavior Checklist, mean arterial pressure, and body mass index were used to determine 
construct validity of 33 items. These items were structured within five domains: pulmonary complaints, school functioning, 
growth and nutrition, exercise and locomotion, emotional functioning and health care concerns. The questionnaire showed 
excellent internal consistency with Cronbach’s alpha of 0.919.
Conclusion This study developed a disease-specific parent-proxy instrument to measure health-related quality of life in 
children with bronchopulmonary dysplasia aged 4–8 years old, the BPD-QoL. All included items show construct validity 
and internal consistency reliability. Future research should focus on further validation and analysis of responsiveness and 
reliability.
Keywords Bronchopulmonary dysplasia · Health-related quality of life · Instrument development · Children
Introduction
Bronchopulmonary dysplasia (BPD) is a chronic lung dis-
ease that affects the mortality and morbidity of children 
born preterm [1, 2]. The pathology and definition of BPD 
is closely associated with low gestational age and low 
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birth weight [3–5]. According to the National Institutes of 
Health Consensus definition, children are diagnosed with 
BPD when they are treated with more than 21% of oxygen 
at 28 days after birth. The severity of BPD is simultaneously 
graded as mild, moderate, or severe based on the respiratory 
support needed at discharge or at 36 weeks post menstrual 
age for children born < 32 weeks or 56 days postnatal age for 
children born ≥ 32 weeks gestational age (whichever comes 
first) [5]. The incidence of BPD found in large studies ranges 
from 25 to 68% in preterm children with a birth weight of 
less than 1500 g [6, 7]. Because of changing definitions and 
the developments in care for premature infants, it is difficult 
to determine the exact prevalence of BPD. It is estimated 
that about 10,000 children in the United States and about 
500–2000 in The Netherlands fulfill the criteria for BPD [8, 
9]. Several studies have shown that children who develop 
BPD experience more problems during childhood, adoles-
cence, and adult age in comparison to children born preterm 
without BPD, as well as healthy controls [2, 10–12]. These 
problems emerge in different areas of functioning. Chest 
symptoms and pulmonary function abnormalities consist of 
airway obstruction, airway hyper reactivity, and hyperinfla-
tion as well as exercise restriction [1, 2, 11]. When compared 
to age-matched controls born at term, respiratory symptoms 
are more common and twice as many children with BPD 
have a diagnosis of asthma during childhood [8]. Because 
of increased vascular resistance in the lungs, children with 
BPD may develop pulmonary hypertension and right ven-
tricular hypertrophy. Left ventricular hypertrophy is also 
seen, possibly associated with systemic hypertension which 
is more commonly found in children with BPD [13–15]. It 
has not been conclusively demonstrated that BPD is inde-
pendently associated with neurodevelopmental problems, 
but it has been shown to be a significant risk factor. Children 
with BPD have a lower intelligence quotient (IQ) with 20% 
achieving full-scale IQ rates < 70. Of children 8 years old 
with BPD, 54% required special education [16]. Underde-
veloped motor skills, both gross and fine, occur more often 
in patients with BPD compared to children with low birth 
weight without BPD and children born at term. More atten-
tion deficit problems are seen: at age 8 years old 15% of chil-
dren with BPD was diagnosed with attention deficit hyperac-
tivity disorder (ADHD), which was significantly more than 
children born at low birth weight (7%) and children born at 
term (4%) [16]. The degree of neurodevelopmental problems 
seems to be associated with the severity of BPD [5, 17]. 
Problems with growth and nutrition are common directly 
after birth, but are also seen later in childhood. The results 
of studies examining delay in growth at older age, however, 
are still inconclusive [18, 19].
Little is known about how these problems affect quality of 
life in children with BPD. Studies in school age children and 
young adults on the follow-up of BPD patients evaluating 
quality of life compared to either children born preterm 
without BPD or healthy controls show inconsistent results. 
Some studies report no significant difference [20–22], while 
other studies found evidence of lower HRQL [23, 24]. How-
ever, quality of life in all these studies was measured with 
a generic questionnaire. For health care purposes, disease-
specific instruments to measure quality of life are known to 
be both more discriminative and responsive when compared 
to generic instruments and therefore are of greater clinical 
significance [25, 26]. For other respiratory conditions, such 
as asthma, cystic fibrosis, vocal cord dysfunction and sleep 
apnea, these instruments have been developed and found to 
be useful both in clinical practice and research [27]. There 
are specific challenges in measuring HRQL in children. 
When children are not able to complete self-report ques-
tionnaires or to understand the concept of quality of life, 
proxy-reports need to be used. There is no set age at which 
children are supposed to be able to self-report on quality of 
life. Of the self-report questionnaires on HRQL developed 
for children below 8 years of age only half of the instruments 
meet minimum standards for internal consistency [28–30]. 
Another important subject is that the perception of quality 
of life is related to age and development. This implies that 
an instrument must be developed and validated for a speci-
fied population. Currently, no disease-specific instrument 
to measure HRQL in children with BPD is available. Such 
an instrument would be very useful in long-term follow-
up of these children since it would better address clinically 
important problems in this age group and consequently help 
to determine therapeutic goals. The aim of this study was to 
develop and validate a disease-specific parent-proxy ques-
tionnaire to measure health-related quality of life in Dutch 
children age 4–8 years old with BPD for future use in both 
research and clinical practice.
Method
Participant selection
The population consisted of 179 children aged 4–8 years old, 
who had been treated in the neonatal intensive care unit of 
the University Medical Center Groningen (UMCG) and met 
the criteria of BPD. This age group was selected because 
HRQL problems associated with BPD are expected to be 
experienced from school age. A proxy report instrument 
was chosen because the target population was 8 years or 
younger and also at increased risk of developmental delay. 
Children with relevant comorbidity that is not described as 
being related to BPD in literature were excluded [31]. Par-
ticipants could only be included in the study if one of the 
parents gave informed consent and the other parent did not 
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object. The study protocol was approved by the medical eth-
ics committee of the UMCG (METc 2011/258).
Item generation
The instrument was developed using the established method 
of item generation, item reduction, and construct valida-
tion [32]. The purpose of item generation was to assemble 
all items that affect quality of life of children with BPD at 
school age. Three sources of information were used: liter-
ature, interviews with doctors with clinical experience in 
follow-up of BPD patients (i.e., neonatologists and pedi-
atric pulmonologists, since they perform the follow-up of 
the patients in The Netherlands) and interviews with a first 
cohort of parents of BPD patients. These interviews were 
semi-structured and completed by one researcher who was 
trained in interviewing patients. The search was considered 
to be complete when no new items emerged. This point 
of saturation was ascertained by the whole research team 
based on the list of items assembled during literature search, 
expert interviews and when two consecutive parent inter-
views elicited no additional items. Additional information 
on participant selection and the process of item generation 
is described in Online Resource 1.
Item reduction
For item reduction, the assembled items were presented to 
the parents of a second cohort of BPD patients. They indi-
cated on a questionnaire for each item if it was relevant to 
their child and to what extent on a 6-point numeric rating 
scale with “0” indicating no burden and “6” extreme burden. 
With the clinical impact method the overall importance (OI) 
of each item was determined as the product of the mean 
importance of an item and the frequency with which it was 
rated [33, 34]. Items with OI > 1 were selected. Items with 
high inter-item correlation (IIC > 0.9) were checked for con-
tent similarity. The item with the lowest OI was removed 
unless the research team decided otherwise. Items with low 
item-total correlation (ITC < 0.2) were discarded [35].
Construct validation and scale development
In a third cohort of BPD patients, parents were asked to rate 
the burden of the previously selected items for their child on 
a questionnaire with a 7-point numeric rating scale ranging 
from 0 (“no burden”) to 7 (“extreme burden”). Therefore, 
higher score reflects worse HRQL. To show construct valid-
ity, one should use an objective parameter that reflects the 
severity of the disease but that is not itself a measure of QoL 
[25]. Five hypotheses were developed to test the construct 
that children age 4–8 years, who fulfill the criteria for BPD 
and who experience complications of BPD at this age, have 
a lower HRQL. These hypotheses can be reviewed in the 
Online Resource 2. Parameters that are generally accepted 
to measure health problems of BPD patients and are eas-
ily obtained in clinical practice were chosen:  FEV1,  FEV1/
FVC, and  FEF25–75 obtained by flow-volume measurement 
and expressed as z-scores [36], body mass index (BMI) in 
z-score [37], mean arterial blood pressure (MAP) in mmHg, 
the standardized T-score of the Dutch version of the age-
specific Child Behavior Checklist (CBCL) with addition of 
the teacher report form (TRF) in children over 6 years old 
[38, 39], and signs of ventricular hypertrophy by screen-
ing of an electrocardiogram (ECG). The outcomes of the 
tests and the items in the questionnaire were then correlated. 
Items that correlated at least moderately and also appropri-
ately with one of the hypotheses that define the construct 
were considered to show construct validity. Items that did 
not show construct validity were removed from the ques-
tionnaire. The remaining items were categorized based on 
an exploratory factor analysis and face validity [35, 40, 41]. 
Because of expected sample size, factor analysis was not 
used to validate the categories but rather to indicate possi-
ble categories. Cronbach’s alpha was calculated to estimate 
internal consistency of the items in the final questionnaire 
[42]. The instrument was developed in the Dutch language.
Data analysis
Differences between groups of participants were evaluated 
with the Student’s t Test, Pearson’s Chi-square Test or Fish-
er’s Exact Test. Differences were considered to be significant 
when P < .05. Correlations were calculated as Spearman’s 
rho (ρs). Correlations were considered high when ρs > 0.50, 
moderate when ρs = 0.35–0.50 and low when ρs < 0.35. Cor-
relations with P < .05 were labeled significant [32]. Statisti-




For item generation, 16 parents (94% mothers) of 19 children 
with BPD and 7 doctors were interviewed. For item reduc-
tion parents of 50 children were approached, of which 32 
responded. One declined participation because of a language 
barrier. For clinical evaluation parents of 110 children were 
approached, of whom 50 responded. Two parents refused 
participation because they did not want an extra hospital 
visit for their child, six parents refused for unknown reasons. 
The characteristics of the three cohorts are documented in 
Table 1; no significant differences were observed. When 
reviewing complications experienced during admission to 
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the neonatal intensive care unit, significantly more grade 
I–II intraventricular hemorrhage occurred in the cohort for 
validation. The incidence of nephrocalcinosis was very low 
in the cohort for item reduction, a difference reaching sig-
nificance when compared to the cohort for validation.
Results of item generation and item reduction
A list of 130 problems was assembled and presented to the 
second cohort of parents of BPD patients for item reduction. 
The clinical impact method identified 52 problems with an 
OI > 1. The correlation matrix revealed 6 pairs of problems 
that had high inter-item correlation. Of three pairs, the one 
with the lowest overall importance was removed. Two pairs 
were found to be clinically different and therefore neither 
item was eliminated. One pair was minimally rephrased to 
become a single item. There was one item with low item-
total correlation which was removed.
Construct validation
The test parameters that showed relevant correlation with the 
items in the questionnaire were spirometry  (FEV1 and FVC), 
BMI, MAP, and the CBCL including TRF. The  FEV1/FVC 
and  FEV25–75 showed correlation with a few items but all 
were weak (ρs < 0.308) and none were statistically significant 
(P > .06). No ECG showed signs of ventricular hypertrophy. 
An overview of the outcome of the tests parameters in the 
cohort of children in the validation phase is summarized in 
Table 2. There were 33 items that showed construct valid-
ity. All listed items and the correlation coefficients with the 
tests parameters that support construct validity are shown 
Table 1  Population 
characteristics per study phase
*As defined by Jobe and Bancalari in Am J Respir Crit Care Med in 2001 [4]
† Significant compared to both identification and clinical impact group (P < 0.05)
‡ Significant compared to clinical impact group (P < 0.05)
Item generation Item reduction Validation
Characteristics
 Participants 19 31 42
 Sex (m/f) 12/7 14/17 27/15
 Age in years (mean ± SD) 6.2 ± 1.6 5.5 ± 1.5 5.7 ± 1.4
 Multiple births (n, %) 9 (47%) 14 (45%) 10 (24%)
 Birth weight in grams (mean ± SD) 950 ± 244 951 ± 308 1041 ± 221
 Days gestational age at birth (mean ± SD) 193.7 ± 11.0 192.5 ± 8.2 195.0 ± 11.9
 Type of BPD*
  Mild (n, %) 8 (42%) 9 (29%) 10 (24%)
  Moderate (n, %) 4 (21%) 13 (42%) 13 (31%)
  Severe (n, %) 7 (37%) 8 (26%) 17 (41%)
  Unknown (n, %) 0 (0%) 1 (3%) 2 (5%)
Neonatal complications
 Necrotizing enterocolitis
  Treated conservatively (n, %) 0 (0%) 2 (7%) 0 (0%)
  Needed surgery (n, %) 2 (11%) 0 (0%) 2 (5%)
 Persistent ductus arteriosus
  Treated with medication (n, %) 8 (42%) 11 (36%) 19 (45%)
  Needed surgery (n, %) 5 (26%) 7 (23%) 7 (17%)
 Intraventricular hemorrhage
  Grade I–II (n, %) 1 (5%) 1 (3%) 8 (19%)‡
  Grade III–IV (n, %) 1 (5%) 3 (10%) 0 (0%)
 Infection
  Sepsis (n, %) 14 (74%) 21 (68%) 27 (64%)
  Pneumonia (n, %) 3 (16%) 8 (26%) 6 (14%)
  Meningitis (n, %) 1 (5%) 2 (7%) 1 (2%)
 Retinopathy of prematurity
  Grade I–II (n, %) 5 (26%) 4 (13%) 7 (17%)
  Grade III–V (n, %) 1 (5%) 1 (3%) 0 (0%)
  Nephrocalcinosis (n, %) 6 (32%) 2 (7%)† 12 (29%)
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in Table 3. The correlation coefficients of all items enter-
ing validation phase have been added in Online Resource 3. 
Items in the domain of pulmonary symptoms did not show 
correlation with the pulmonary function tests but with the 
results of the TRF. All items concerning school function-
ing correlated with results of the TRF. The vast majority 
of items concerning growth and nutrition correlated with 
BMI, except the items ‘vomiting easily’ which correlated 
with MAP and ‘stomach ache’ which correlated with the 
CBCL. The items concerning exercise and locomotion cor-
related most strongly with pulmonary function results. In 
this category, the problems focusing on exercise instead of 
locomotion also correlated significantly with MAP. Items 
in ‘emotional functioning and health care concerns’ showed 
correlation with the CBCL and TRF sum scales. Analysis 
of the item responses show that most of the participants 
report a burden of 1–2 on the numeric rating scale (between 
‘barely’ or ‘a little bit’) and only few participants report 
the highest burden. Mean responses with floor and ceiling 
effects are presented in Table 4.
Scale development and internal consistency
Principal component analysis with varimax rotation cate-
gorized items into six domains [35, 41]. The sixth domain 
contained only one item (‘stomach ache due to constipa-
tion’); therefore, this item was replaced within the domain 
it fit next best in. Four other items were replaced in a 
more appropriate domain based on face validity and the 
pattern of correlation they showed with the test param-
eters. The five domains were named ‘pulmonary com-
plaints,’ ‘school functioning,’ ‘growth and nutrition,’ 
‘exercise and locomotion,’ and ‘emotional functioning 
and health care concerns.’ The questionnaire showed 
excellent internal consistency with Cronbach’s alpha of 
0.919 and all domains having Cronbach’s alpha exceeding 
0.70. Since items have been deleted during the validation 
process, we chose not to evaluate the internal consistency 
of the total score. An English translation of the Dutch 
questionnaire, named BPD-QoL, was added to function 
as an example in Online Resource 4.
Discussion
With this study, a Dutch parent-proxy disease-specific 
quality of life questionnaire for children with BPD aged 
4–8 years old (the BPD-QoL) was developed and evaluated 
for construct validation and internal consistency reliability. 
This is an important step in developing structured care for 
these patients since it allows clinicians to aim therapeutic 
interventions at perceived burdens instead of performing 
follow-up of the possible physical complications of BPD 
that might not be relevant to the child’s quality of life.
Item generation and item reduction
The process of item generation and item reduction was 
most essential to ensure the development of a complete and 
relevant questionnaire. Item generation relied not only on 
existing literature and the opinion of experts, but also on the 
input from parents of patients. In total, 16 interviews were 
conducted in a representative sample. This is an adequate 
amount for item generation [43]. For item reduction, the 
clinical impact method was used, rather than factor analy-
sis. Literature showed that either method can show different 
results in questionnaire development, but one is not superior 
to the other [33, 34]. Since this instrument was developed 
for clinical practice and clinical research, showing clinical 
Table 2  Outcome of the test 
parameters in validation phase
FEV1 forced expiratory volume in 1  s, FVC forced vital capacity, FEV25–75 forced expiratory volume at 
25–75% of FVC, CBCL child behavior checklist, CBCL-TOT total scale of CBCL, TRF teacher report 
form, TRF-TOT total scale of TRF, TRF-AF scale sum of academic functioning of TRF
Parameter Number of par-
ticipants
Value (mean ± SD) Z-score (mean ± SD)
Height (m) 42 1.17 ± 0.10 − 0.72 ± 0.96
Weight (kg) 42 20.91 ± 0.96 − 0.84 ± 1.06
Body Mass Index 42 15.01 ± 1.42 − 0.53 ± 0.88
Mean arterial pressure (mmHg) 42 73.36 ± 9.07
FEV1 (l) 40 1.15 ± 0.31 − 0.88 ± 0.97
FVC (l) 38 1.43 ± 0.39 − 0.11 ± 0.99
FEV1/FVC (%) 38 81.86 ± 7.61 − 1.47 ± 0.93
FEV25–75 (l) 38 1.18 ± 0.43 − 1.48 ± 1.01
CBCL-TOT (T-score) 36 51.33 ± 9.48
TRF-TOT (T-score) 19 48.47 ± 7.37
TRF-AF (T-score) 19 48.53 ± 0.43
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impact was of most importance for items in the question-
naire. Item reduction resulted in an acceptable number of 
items.
Process of construct validation
Subsequently, it was determined if the identified items were 
reliable and valid for the purpose of measuring HRQL 
[25, 26]. In the absence of a gold standard measurement, 
Table 3  Correlation coefficients supporting construct validity for the items in the BPD quality of life questionnaire (BPD-QoL) with the selected 
measurements and internal consistency of the domains
Significant correlations (P < 0.05) are marked in bold
BMI body mass index, MAP mean arterial pressure, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, CBCL-TOT total scale of 
child behavior checklist, TRF-TOT total scale of teacher report form, TRF-AF scale sum of academic functioning of teacher report form, α Cron-
bach’s alpha
Items of BPD-QoL BMI MAP FEV1 FVC CBCL-TOT TRF-TOT TRF-AF α
Number of participants 42 42 40 38 36 19 19
Pulmonary symptoms 0.925
 Wheezing 0.359
 Sputum in throat or airways 0.402
 Dyspnea when having a cold 0.391 0.359
 Having a cold more often 0.467
 Having a cold that lasts longer 0.588
 Bronchial hyperreactivity 0.446
School functioning 0.925
 Difficulty progressing in school 0.621 0.385
 Needing extra support at school 0.595 0.402
 Difficulty concentrating 0.659
 Being easily distracted 0.624
 Requiring a lot of structure daily 0.466
 Difficulty with arithmetic 0.407
 Difficulty with grammar 0.371
Growth and nutrition 0.845
 Stomach ache due to constipation 0.590
 Difficulty eating a serving of food 0.381
 Taking a long time when eating 0.395
 Often don’t want to eat
 Feeling cold easily 0.419
 Vomiting easily 0.422
 Being sensitive to loud noises 0.419
Exercise and locomotion 0.850
 Problems in physical education/sports 0.430 0.542
 Problems practicing swimming 0.481 0.437 0.404
 Easily tripping or falling 0.413 0.397
 Problems with cycling 0.468 0.424 0.388
 Problems with coordination or balance 0.427 0.438
 Exertional dyspnea 0.360 0.419
 Not keeping up in exercise/playing 0.385 0.367
Emotional functioning and health care concerns 0.778
 Consults with the general practitioner 0.361 0.454
 Feeling less self-confident 0.406
 Fear of being left alone by parent(s) 0.369
 Being shy 0.453
 Having scars of surgeries, punctures or intravenous lines 0.452
 Frequent need to use medication 0.511
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construct validity is the best type of validity that can be 
achieved [25]. Construct validity is based on the concept that 
items of disease-specific HRQL instruments should be at 
least moderately correlated to an independent measure of the 
same disease. This method is established and has success-
fully been used in the development of HRQL instruments 
[44]. There is no clinical consensus on how to measure the 
severity of BPD at school age independently. Therefore, we 
chose five measurements of functioning that are widely used 
in the follow-up and determination of complications of BPD 
[31]. The results of this analysis led to the deletion of 14 
items that did not show construct validity. Factor analysis 
was used to investigate the amount of domains and which 
items they should contain. The sample size in our study was 
not sufficient for a reliable exploratory factor analysis and 
the Kaiser–Meyer–Olkin measure of sampling adequacy was 
only 0.373 [35, 41]. Factor analysis was therefore used as an 
indication and the final decision on number of domains and 
items added to them was made by the research team.
For evaluation of internal consistency of the developed 
questionnaire and domains, Cronbach’s alpha was deter-
mined. This is a measure of scale reliability and the coef-
ficient indirectly estimates to which degree a set of items 
measures a single construct [42]. The value that Cronbach’s 
Table 4  Mean, standard 
deviation, and spread of 
responses of the 33 final items 
of BPD-QoL
N number of participants, SD standard deviation






Coughing 42 2.12 (1.50) 19.0 0.0
Impaction of mucus in airways 41 1.78 (1.29) 19.5 0.0
Sputum in throat or airways 42 1.64 (1.50) 31.0 0.0
Dyspnea when having a cold 42 1.86 (1.69) 33.3 0.0
Having a cold more often 42 1.90 (1.82) 35.7 0.0
Having a cold that lasts longer 42 1.90 (1.82) 35.7 2.4
Bronchial hyperreactivity 41 1.93 (1.88) 36.6 2.4
Having earpain/otitis 42 1.14 (1.26) 42.9 0.0
Difficulty progressing in school 42 1.12 (1.69) 59.5 2.4
Needing extra support at school 42 1.21 (1.69) 57.1 2.4
Difficulty concentrating 42 2.21 (1.87) 28.6 2.4
Being easily distracted 42 2.31 (1.92) 28.6 2.4
Requiring a lot of structure daily 42 2.48 (1.76) 23.8 2.4
Difficulty with arithmetic 42 0.98 (1.66) 71.4 0.0
Difficulty with grammar 41 1.05 (1.70) 68.3 0.0
Difficulty eating a serving of food 42 1.74 (1.70) 35.7 2.4
Taking a long time when eating 42 1.55 (1.70) 42.9 0.0
Often don’t want to eat 42 1.26 (1.55) 47.6 0.0
Feeling cold easily 42 1.55 (1.69) 45.2 0.0
Being sensitive to loud noises 42 1.57 (1.92) 47.6 4.8
Problems in physical education/sports 42 0.81 (1.23) 61.9 0.0
Problems practicing swimming 40 1.20 (1.86) 67.5 0.0
Easily tripping or falling 42 1.52 (1.53) 35.7 2.4
Problems with cycling 42 0.67 (1.05) 66.7 0.0
Problems with coordination or balance 42 1.02 (1.14) 45.2 0.0
Exertional dyspnea 42 1.26 (1.56) 50.0 0.0
Not keeping up in exercise/playing 42 0.95 (1.32) 57.1 0.0
Trouble parting from parent(s) 42 1.12 (1.55) 52.4 0.0
Withdrawal from social situations 42 1.14 (1.35) 50.0 0.0
Consults with the general practitioner 42 0.86 (1.22) 54.8 0.0
Feeling less self-confident 42 1.55 (1.57) 38.1 0.0
Fear of being left alone by parent(s) 42 1.21 (1.62) 50.0 2.4
Being shy 42 1.76 (1.43) 26.2 0.0
Having scars of surgeries, punctures or 
intravenous lines
42 1.50 (1.57) 40.5 0.0
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alpha should reach to prove internal consistency of an HRQL 
instrument is not definite. In literature on scale development 
and psychometric properties an alpha value from 0.50 to 
greater than 0.90 can be recommended, depending on the 
purpose of the instrument [40, 45]. A value > 0.70 is gener-
ally accepted to prove good internal consistency in previ-
ously developed HRQL instruments [44, 46].
One difficulty in determining construct validity is that 
selected clinical parameters are not always able to reflect 
the severity of the problems as experienced by patients. As 
was also demonstrated in this study, there is lack of correla-
tion between burden of pulmonary symptoms and pulmo-
nary function parameters. This has been shown previously 
in asthma [47, 48] and chronic cough [49]. In our study, 
pulmonary function tests show moderate correlation with 
problems experienced in exercise and locomotion. An ECG 
can be used as a screening tool for right ventricular hypertro-
phy as a sign of pulmonary hypertension (PH), even though 
it is not a very sensitive tool [50]. It showed no value in 
determining construct validity for the questionnaire since 
the results showed no signs of PH in our population. In this 
study, we evaluated MAP as a parameter of cardiovascular 
functioning. The expectation was that it would be correlated 
to problems in exercise. Some correlation was found but this 
was quite modest. The item ‘vomiting easily’ correlated with 
MAP; however, this is not considered to be a problem in 
cardiovascular functioning. Otherwise there was not much 
value for measurement of MAP in determining construct 
validity. The choice to use the total score of the CBCL was 
made when we reviewed the correlations and determined 
that the total score included basically all relevant correla-
tions found in the subscales. Correlations in the total score 
are however weakened since it contains many subscales. 
For example, there is weak correlation with problems of 
withdrawal and lack of self-confidence. When looking at 
the CBCL subscale on ‘withdrawal,’ stronger correlations 
are found. The sample size that completed the TRF in our 
study was small but the correlation with items concerning 
school functioning suggests that it is a valuable test to evalu-
ate the burden of problems in school functioning in children 
with BPD. The TRF correlated with many different items in 
some way, suggesting that these tests explore a large area 
of functioning of the child. A footnote to the CBCL is that 
it is designed for children in general and is not specifically 
validated for the clinical setting.
Limitations
There were only a few exclusion criteria for the participants. 
This made it possible to include a considerable number of 
children and to apply the results of this study to a broad pop-
ulation of children with BPD. On the other hand, comorbid-
ity could have influenced both the test results and the results 
of the questionnaire. In order to minimize this problem, par-
ents were asked to answer questions with the relationship 
of the child’s problems to BPD in mind. All children in our 
study were of low gestational age and low birth weight. The 
results of the study could partly be caused by solely these 
conditions without an attributional effect of BPD itself. It is 
however not of clinical use to make a distinction between 
these conditions. One could expect some overlap of items 
when developing a HRQL instrument for children of low 
gestational age and/or low birth weight; this has not yet been 
investigated. We considered these conditions to be so much 
related to BPD that their influence on quality of life should 
be captured within our developed instrument. Overall, the 
number of participants in the item reduction and validation 
phase is small due to the fact that BPD does not have very 
high prevalence and it is difficult to select a population that 
does in fact fulfill the set criteria. Also there is not a 100% 
response rate in the follow-up population. Because item gen-
eration was limited by resources and number of participants, 
no focus groups and no recordings of interviews were col-
lected. Content validity could have been elaborated further 
by conducting cognitive interviews and collecting qualita-
tive data on item saturation, as is currently recommended in 
developing patient-reported outcome measures [51]. In the 
item reduction phase, a satisfactory response rate of 64% 
was reached. However within the selected population for the 
validation phase, there was a large group of parents that did 
not respond to our request to participate or refused to par-
ticipate (62%). The low response rate could be due to the fact 
that the research required responders to visit the hospital. 
Descriptive data from the non-responders were not available. 
When analyzing descriptive data of the items, we found a 
substantial portion of our participants reported no burden 
for the selected items. This can be expected since survivors 
of BPD are at increased risk of developing complications 
but not all patients are affected. We consider our included 
population as a representative sample of the target popu-
lation. However, from a psychometric point of view, such 
floor effects are high [52] and could limit the item validity 
and reliability. Adequate variation remains captured by the 
items in the BPD-QoL since Cronbach’s alpha is not too high 
for an HRQL instrument [44], as one would expect when 
items are too interrelated. Finally, the choice of creating a 
parent-proxy instrument can be considered to be a limita-
tion since this is not a substitute for an individual’s own 
information [28, 30]. Although self-report instruments have 
been developed for children under 8 years old, these show 
more frequently to be of lower reliability [29, 30]. We found 
this not to be a valid option in our population when taking 
into account the possible developmental delay in patients 
with BPD. Even though large differences can be found when 
comparing reports of children to their parents on HRQL, 
parent-proxy measurement of quality of life has shown to 
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be valid [53]. Proxy-reports are likely to be most accurate 
when items focus on observational content [30], as they do 
in the BPD-QoL. However, when developing an instrument 
to measure HRQL in children with BPD above 8 years old, 
a patient reported outcome measure is recommended [30].
For use in other languages, the Dutch instrument should 
be translated and validated in that language [54]. The instru-
ment should be evaluated further for convergent and diver-
gent validity, longitudinal validity, reliability, and respon-
siveness to determine its suitability for use in follow-up and 
research on HRQL in children with BPD.
Conclusion
This is the first reported disease-specific instrument to meas-
ure parent-proxy HRQL in children 4–8 years old with BPD. 
It provides a first step in meeting the need of acquiring more 
accurate measurements of HRQL in this population. Meas-
uring HRQL is useful in determining the long-term effects 
and evaluating treatment options. The instrument devel-
oped in this study showed construct validity and internal 
consistency but further analysis of reliability and validity 
is necessary.
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